TP53 and ovarian carcinoma: Currently, there are over 170 ongoing clinical trials mostly for malignant solid tumours, non-small cell lung carcinoma, breast carcinoma, ovarian carcinoma and acute myeloid leukaemia in which TP53 status serves as an inclusion eligibility criteria [1].